On the 9th of September, we had the pleasure to meet the Czech and Polish investigators in the OXOART2 Investigators … [Read more...] about Good feelings in the investigators meetings
Last Thursday 2nd of September, we had the pleasure to celebrate the first investigator meeting of the phase II clinical … [Read more...] about OXOART2 is here: First Investigators Meeting
OXOLIFE is developing the first drug that will treat female infertility by improving the endometrium to enhance the … [Read more...] about UNPRECEDENTED APPROACH: Oxolife shows up in El Punt Avui
Oxolife will present its newest evidences on OXO-001 in fertility and embryo implantation in the American Society for … [Read more...] about OXOLIFE presents the latest results in the ASRM21
Today, Oxolife founders Agnès Arbat and Ignasi Canals are in the international event 4YFN - 4 Years from Now, hold in … [Read more...] about OXOLIFE IS PRESENT IN THE 4YFN – MWC
The European Society of Human Reproduction and Embryology (ESHRE) has accepted our second communication for its … [Read more...] about OXOLIFE has two accepted communications in the ESHRE Annual Meeting
The Ministry of Science and Innovation has awarded us the seal of small and medium-sized innovative company. From now … [Read more...] about Oxolife has been recognized as an innovative SME
Today we have a BIG new! We want to announce that the protocol and documents for the phase II clinical trial of … [Read more...] about The phase II clinical trial protocol and documents have been submitted!
The video presentation of Oxolife as a new member of CataloniaBio Health Tech has already come to light. We are very … [Read more...] about We are Catalonia BioHT!
At the end of June, the European Society of Human Reproduction and Embryology (ESHRE) organizes its 37th Annual Meeting … [Read more...] about OXOLIFE will participate in the ESHRE 37th Annual Meeting